Business
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
Only Program that has Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Preservation of Photoreceptors in the
About this update from Annexon, Inc.
[{"type":"text","content":"Only Program that has Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Preservation of Photoreceptors in the Fovea Region Critical for Visual Acuity Pivotal Phase 3 ARCHER II in GA Actively Enrolling with Data Expected Second Half 2026 BRISBANE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the company will present analyses of ANX007 from the completed Phase 2 ARCHER trial in geographic atrophy (GA) at the Floretina-ICOOR 2024 meeting being held December 5-8 in Florence, Italy. ANX007 is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. Details of the presentations are as follows: “Unlocking Structure/Function Relationships in GA: Central Subdomain Preservation and Visual Acuity Protection with C1q Inhibition” Session: Podium presentationPresenter: Dr. Jeffrey S. Heier, Ophthalmic Consultants of Boston, and investigator in ARCHERDate/Time: Thursday, December 5, 2024, 15:12-15:15 pm CESTLocation: San Frediano Room “Prevention of Visual Acuity Loss and Preservation of Photoreceptors by ANX007 in Dry Age-Related Macular Degeneration (AMD)/Geographic Atrophy (GA) in the Phase 2 ARCHER Trial, Including in Patients with Less Advanced Disease” Session: Podium presentationPresenter: Dr. Paulo Eduardo Stanga, The Retina Clinic London and Institute of Ophthalmology, University College London, UKDate/Time: Thursday, December 5, 2024, 15:21-15:24 pm CESTLocation: San Frediano Room Annexon Symposium: “Protection of Vision and Structure in GA” “C1q Driven Neurodegeneration: Impacts on Structure and Function” Dr. Peter Kaiser, Cleveland Clinic of Ohio “ANX007: Visual Acuity Protection and Safety in the Phase 2 ARCHER Trial” Dr. Charles C. Wykoff, Research Institute at Houston Methodist, Weill Cornell Medical College, Retina Consultants of Texas, and an investigator in ARCHER “Linking Structure to Function: Protection of Vision-Associated Structures with ANX007” Dr. Anat Loewenstein, Tel Aviv Medical Center Date/Time: Friday, December 6, 2024, 13:45-16:30 pm CESTLoca...